Dr. David Newman Joins Board of CardioComm Solutions, Inc.

Victoria, B.C., June 14, 2010 – CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm” or the “Company”) announced that Dr. David Newman was elected to the board of directors of the Company at the Company’s annual general meeting of shareholders on June 8, 2010. The incumbent directors of the Company, Dr. Anatoly Langer, Etienne Grima, William Smith and Yury Levin, were also re-elected at the meeting.

Dr. Newman is an Associate Professor in the faculty of medicine at the University of Toronto. He received his medical training at Dalhousie University (medicine) and the University of Toronto (internal medicine, cardiology), followed by post-doctoral training at the University of California San Francisco and Stanford University. He is a recognized expert in the field of cardiac arrhythmias and their management and has extensive experience with outpatient cardiac recording devices and their uses. The credentials of the other directors of the Company can be found in the Company’s management information circular respecting the meeting at www.sedar.com.

Dr. Anatoly Langer, the Chairman of the board of the Company, said “David brings a wealth of experience and recognition to the board, and I am sure his insight and knowledge will be of immense help in defining our business strategy and executing it with our customers.”

About CardioComm Solutions, Inc.
CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company’s products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm’s software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

“Anatoly Langer”

Anatoly Langer, Chairman of the Board

For investor information, please contact:
Etienne Grima, Chief Executive Officer
1.800.725.6585, ext. 229
www.cardiocommsolutions.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release